PCMA Blog
From Promise to Progress: The Rise of Biosimilars
By Amanda Frost, PhD Vice President, Research, PCMA I have been watching the biosimilar market for several years now, and
Competition Can’t Wait: Policymakers Must Address Patent Abuse
The best way to lower drug prices is by encouraging competition in the market. When more options are available, prices
The Real Test for DOL’s Proposed PBM Rule: Is It Helping or Hurting Affordability?
This week, leaders from the Department of Labor (DOL), Department of Health and Human Services (HHS), and Centers for Medicare
GAO: Both Gross and Net Payments Higher for Independent Pharmacies
Yesterday, we highlighted a new report from the U.S. Government Accountability Office (GAO) that factually shows a much different picture
New NCPA Data Finds Independent Pharmacies Are Strong. Policymakers Can Help Them Do Even More.
The independent pharmacy market remains strong and stable. That is according to the latest findings in the National Community Pharmacists
GAO: Unaffiliated Pharmacies Reimbursed at Higher Rates than PBM-Owned Pharmacies
A new report from the U.S. Government Accountability Office (GAO) found that in Medicare Part D, PBMs paid independent pharmacies
Dual Reports: Restricting Pharmacy Ownership Will Hurt Access for Patients
A new report from the Goldwater Institute warns that proposals to restrict pharmacy ownership could reduce access to care and
Three Questions DOL Should Answer Before Finalizing Its PBM Rule
Through changes to business models and a sweeping new federal law, pharmacy benefit managers (PBMs) are already well on their